Stocktoria
Ernexa Therapeutics Inc. ERNA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1991-08-29
Ernexa Therapeutics Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $582,000 | $68,000 | $0 | — | $5.8M | $19.8M | $23.3M | $21.3M | $22.3M |
| Gross profit | — | $486,000 | -$168,000 | $0 | — | — | — | — | — | — |
| R&D expense | — | — | — | — | — | $2,000 | $26,000 | $72,000 | $139,000 | — |
| SG&A expense | — | — | — | — | — | $8.1M | $13.2M | $14.5M | $15.6M | $16.5M |
| Operating income | -$9.3M | -$15.7M | -$21.1M | -$33.2M | -$113.7M | -$26.5M | -$1.8M | $203,000 | -$1.4M | -$2.3M |
| Interest expense | — | — | $614,000 | $30,000 | — | — | — | — | — | — |
| Income tax | -$45,000 | $30,000 | -$3,000 | $45,000 | $64,000 | $0 | $27,000 | -$64,000 | $66,000 | $38,000 |
| Net income | -$14.1M | -$44.5M | -$21.7M | -$24.6M | -$122.5M | -$26.5M | -$2.0M | -$259,000 | -$1.1M | -$2.9M |
| EPS (diluted) | $-2.24 | $-48.96 | $-4.08 | $-8.06 | $-56.61 | $-1.51 | — | — | — | — |
| Operating cash flow | -$7.0M | -$15.8M | -$20.4M | -$21.0M | -$23.5M | -$8.1M | $2.7M | $1.4M | $549,000 | $23,000 |
| Free cash flow | -$7.1M | -$16.2M | -$20.4M | -$21.3M | -$23.6M | -$8.1M | $2.6M | $717,000 | -$179,000 | -$404,000 |
| Cash & equivalents | — | $1.7M | $7.6M | $11.4M | $17.0M | $777,000 | $3.2M | $2.5M | $3.4M | $5.7M |
| Total assets | $5.8M | $5.3M | $49.1M | $22.3M | $31.5M | $13.8M | $14.1M | $14.9M | $16.6M | $16.7M |
| Total liabilities | $3.4M | $3.6M | $46.9M | $10.2M | $6.0M | $25.4M | $9.0M | $7.9M | $11.0M | $12.6M |
| Shareholders' equity | $2.4M | $1.7M | $2.2M | $12.1M | $25.5M | $7.7M | $9.7M | $6.9M | $5.5M | $4.1M |
Growth · year-over-year · Revenue CAGR -40.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | +755.9% | — | — | — | -70.7% | -15.1% | +9.7% | -4.7% | -9.0% |
| Free cash flow growth | — | — | — | — | — | -411.2% | +264.9% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.